Introduction
============

Stroke is a common and serious condition, with approximately 795,000 individuals having experienced a new or recurrent stroke and 128,978 stroke-related deaths having occurred in the United States in 2013. The prevalence of stroke in the United States was approximately 6.6 million in 2012, with 87% of these events being ischemic stroke, 10% intracerebral hemorrhage (ICH) and 3% subarachnoid hemorrhage (SAH) ([@b1-ijmm-39-06-1477]). Despite recent advances in acute therapy, stroke remains the leading cause of severe disability and the fifth leading cause of mortality (after heart disease, cancer, chronic lower respiratory disease and accidents) in the United States ([@b1-ijmm-39-06-1477]). Given that stroke is a life-threatening condition, its prevention is an important goal for reducing its overall burden. The identification of biomarkers for stroke risk is key both for risk prediction and for potential intervention to avert future cerebrovascular events.

Ischemic stroke is a complex multifactorial disorder that is thought to result from an interaction between a person\'s genetic background and various environmental factors ([@b2-ijmm-39-06-1477]). The heritability of ischemic stroke has been estimated to be 40.3% for large-vessel disease, 32.6% for cardioembolic stroke, 16.1% for small-vessel disease and 37.9% for ischemic stroke as a whole ([@b3-ijmm-39-06-1477]). Genome-wide association studies (GWASs) in European ancestry populations have identified various genes and loci that confer susceptibility to ischemic stroke ([@b4-ijmm-39-06-1477]--[@b11-ijmm-39-06-1477]), with one recent large-scale study having identified *HDAC9* and chromosome 1p13.2 (near *TSPAN2*) as susceptibility loci for large-vessel disease, *PITX2* and *ZFHX3* as such loci for cardioembolic stroke, and 12q24 (near *ALDH2*) as a susceptibility locus for small-vessel disease, indicating that ischemic stroke-related loci are subtype specific ([@b12-ijmm-39-06-1477]).

ICH accounts for a large proportion of severe or fatal cases of stroke, with its most important risk factors being advanced age and hypertension ([@b13-ijmm-39-06-1477]). ICH is usually attributed to hypertensive small-vessel disease, with the most common sites of hemorrhage including the basal ganglia, cerebellum and pons ([@b13-ijmm-39-06-1477],[@b14-ijmm-39-06-1477]). In some cases, however, the hemorrhage is lobar in location, such as in the frontal, parietal, temporal or occipital cortex, and such patients often do not have hypertension ([@b14-ijmm-39-06-1477]). The occurrence of lobar ICH has been shown to be associated with the ε2 and ε4 alleles of the apolipoprotein E gene (*APOE*) ([@b15-ijmm-39-06-1477],[@b16-ijmm-39-06-1477]). This relation of lobar ICH to *APOE* is presumably due to the association of this gene with cerebral amyloid angiopathy ([@b17-ijmm-39-06-1477]). The heritability of deep or lobar ICH has been estimated to be 34 and 73%, respectively ([@b18-ijmm-39-06-1477]), although genetic factors may influence, not only the development of ICH, but also hypertension ([@b19-ijmm-39-06-1477]). A previous meta-analysis of GWASs for ICH in European ancestry populations identified chromosome 12q21.1 (near *TRHDE*) as a susceptibility locus for lobar ICH and 1q22 (near *PMF1-SCL25A44*) as such a locus for nonlobar ICH ([@b20-ijmm-39-06-1477]).

SAH is commonly caused by the rupture of an aneurysm in an intracranial artery ([@b21-ijmm-39-06-1477],[@b22-ijmm-39-06-1477]). Although the incidence of aneurysmal SAH in the general population is low (\~8/100,000 person-years) ([@b23-ijmm-39-06-1477]), a young age at onset and poor prognosis result in the loss of productive life-years similar to that for ischemic stroke ([@b24-ijmm-39-06-1477]). Given that a family history is an important risk factor for the development of intracranial aneurysm, genetics may play an important role in the development of this condition ([@b25-ijmm-39-06-1477]). GWASs have implicated several loci and genes as conferring susceptibility to intracranial aneurysm ([@b26-ijmm-39-06-1477]--[@b31-ijmm-39-06-1477]), with a meta-analysis of such studies having identified 19 genetic variants related to this condition ([@b32-ijmm-39-06-1477]).

Most genetic variants identified by GWASs for ischemic stroke, ICH, or intracranial aneurysm have a minor allele frequency (MAF) of \>5% and a small individual effect size. Given that these common variants explain only a fraction of the heritability of ischemic and hemorrhagic stroke, it is expected that low-frequency (MAF of 0.5--5%) or rare (MAF of \<0.5%) variants with larger effect sizes contribute to the genetic architecture of these conditions ([@b33-ijmm-39-06-1477]). Although several polymorphisms have been found to be significantly associated with ischemic stroke ([@b34-ijmm-39-06-1477]--[@b36-ijmm-39-06-1477]) or intracranial aneurysm ([@b30-ijmm-39-06-1477]) in Japanese individuals, genetic variants, including low-frequency and rare variants, that contribute to genetic susceptibility to ischemic stroke, ICH or SAH in Japanese individuals remain to be identified definitively.

In this study, we performed exome-wide association studies (EWASs) with the use of exome array-based genotyping methods to identify single nucleotide polymorphisms (SNPs) and in particular, low-frequency or rare coding variants with moderate to high effect sizes, that confer susceptibility to ischemic stroke, ICH, or SAH in Japanese individuals. Given that most of the known low-frequency or rare variants were not included in the arrays adopted in previous GWASs for these conditions, we applied Illumina arrays that provide coverage of functional SNPs in entire exons, including such variants.

Materials and methods
=====================

Study subjects
--------------

For EWAS of ischemic stroke, 1,575 patients with ischemic stroke and 9,210 control individuals were examined, whereas for EWASs of hemorrhagic stroke, 673 patients with ICH, 265 patients with SAH and 9,158 controls were examined. The majority of the control individuals were the same for the studies of ischemic and hemorrhagic stroke. The subjects were recruited from individuals who either visited outpatient clinics of or were admitted to participating hospitals (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Inabe General Hospital, Inabe; Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki, Japan) due to various symptoms or for an annual health checkup between 2002 and 2014; were community-dwelling individuals recruited to a population-based cohort study in Inabe between 2010 and 2014 or in Tokyo or Kusatsu between 2011 and 2015; or were cases of autopsy performed at the Tokyo Metropolitan Geriatric Hospital from 1995 to 2012.

The diagnosis of ischemic stroke, ICH, or SAH was based on the occurrence of a new and abrupt focal neurological deficit, with neurological symptoms and signs persisting for \>24 h, and it was confirmed by positive findings in computed tomography or magnetic resonance imaging (or both) of the head. The type of stroke was determined according to the Classification of Cerebrovascular Diseases III ([@b37-ijmm-39-06-1477]). Given that susceptibility loci for ischemic stroke are subtype-specific ([@b12-ijmm-39-06-1477]), we examined subjects with atherothrombotic cerebral infarction (large-vessel disease).

For the study of ischemic stroke, subjects with cardiogenic embolic stroke, lacunar infarction alone, transient ischemic attack, hemorrhagic stroke, cerebrovascular malformations, moyamoya disease, cerebral venous sinus thrombosis, brain tumors, or traumatic cerebrovascular diseases were excluded from enrollment. For the studies of hemorrhagic stroke, individuals with ischemic stroke, lacunar infarction, transient ischemic attack, intracranial hemorrhage resulting from cerebrovascular malformations, moyamoya disease, cerebral venous sinus thrombosis, brain tumors, traumatic cerebrovascular diseases, or subdural hematoma were excluded. The control individuals had no history of ischemic or hemorrhagic stroke; of aortic, coronary, or peripheral artery disease; or of other thrombotic, embolic or hemorrhagic disorders. Individuals with unruptured intracranial aneurysm were also excluded from the controls. The absence of stroke history was evaluated with a detailed questionnaire and was confirmed by the absence of a history of neurological deficits. Autopsy cases were excluded from the controls.

Body mass index was calculated as follows: body mass index = body weight (kg)/\[body height (m)\]^2^. Blood pressure was measured at least twice with subjects having first rested in the sitting position for \>5 min; the measurements were taken by a skilled physician or nurse. Venous blood was collected in the early morning after the subjects had fasted overnight. Plasma glucose level, blood hemoglobin A~1c~, and serum concentrations of triglycerides, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, and creatinine were measured with automated analyzers at the clinical laboratory of each hospital. Estimated glomerular filtration rate (eGFR) was calculated as follows: eGFR (ml/min/1.73 m^2^) = 194 × \[age (years)\]^−0.287^ × \[serum creatinine (mg/dl)\]^−1.094^ × \[0.739 if female\]. Chronic kidney disease was defined as an eGFR of \<60 ml/min/1.73 m^2^.

The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine, Tokyo Metropolitan Institute of Gerontology, Hirosaki University Graduate School of Medicine, and participating hospitals. Written informed consent was obtained from each participant or the families of the deceased subjects.

EWASs
-----

Venous blood (5 or 7 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated and genomic DNA was extracted from these cells either with a DNA extraction kit (Genomix; Talent, Trieste, Italy; or SMITEST EX-R&D; Medical and Biological Laboratories, Nagoya, Japan) or by standard protocols based on phenol-chloroform extraction and spin columns. In autopsy cases, genomic DNA was extracted from the kidneys. EWASs were performed with the use of a HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA), both of which include putative functional exonic variants selected from \>12,000 individual exome and whole-genome sequences. The exonic content of \~244,000 SNPs represents diverse populations, including European, African, Chinese and Hispanic individuals ([@b38-ijmm-39-06-1477]). SNPs contained in only one of the exome arrays (\~3.6% of all SNPs) were excluded from the analysis. We performed quality control ([@b39-ijmm-39-06-1477]) as follows: i) genotyping data with a call rate of \<97% were discarded, with the mean call rate for the remaining data being 99.9%; ii) sex specification was examined for all samples, and those for which sex phenotype in the clinical records was inconsistent with genetic sex were discarded; iii) duplicated samples and cryptic relatedness were examined by calculation of identity by descent; all pairs of DNA samples showing identity by descent of \>0.1875 were inspected, and one sample from each pair was excluded; iv) heterozygosity of SNPs was calculated for all samples, with those showing extremely low or high heterozygosity (\>3 standard deviations from the mean) being discarded; v) SNPs in sex chromosomes or in mitochondrial DNA were excluded from the analysis, as were non-polymorphic SNPs or SNPs with a MAF of \<0.001; vi) SNPs whose genotype distributions deviated significantly (P\<0.001) from Hardy-Weinberg equilibrium in control individuals were discarded; vii) genotype data were examined for population stratification by principal components analysis ([@b40-ijmm-39-06-1477]), and population outliers were excluded from the analysis. A total of 41,339 and 41,332 SNPs that passed quality control for the studies of ischemic and hemorrhagic stroke, respectively, were subjected to analysis.

Statistical analysis
--------------------

For the analysis of characteristics of the study subjects, quantitative data were compared between subjects with ischemic stroke, ICH or SAH and controls with the Mann-Whitney U test, given that variables exhibited skewed distribution (P\<0.01 by the Kolmogorov-Smirnov and Lilliefors test). Categorical data were compared between two groups with Fisher\'s exact test. Allele frequencies were estimated by the gene counting method, and Fisher\'s exact test was applied to identify departure from Hardy-Weinberg equilibrium. Allele frequencies of SNPs were compared between subjects with ischemic stroke, ICH or SAH and the controls with Fisher\'s exact test. Given that the Fisher\'s exact test gives exact P-values, it is appropriate to use this test to examine the relation of low frequency or rare variants to phenotypes. To compensate for multiple comparisons of genotypes with ischemic stroke, ICH or SAH, we applied Bonferroni\'s correction for statistical significance of association. Given that 41,339 or 41,332 SNPs were analyzed for ischemic and hemorrhagic stroke, respectively, the significance level was set at P\<1.21×10^−6^ (0.05/41,339 or 0.05/41,332) for each EWAS. Quantile-quantile plots for P-values of allele frequencies in EWASs for ischemic stroke, ICH and SAH are shown in [Fig. 1](#f1-ijmm-39-06-1477){ref-type="fig"}. The inflation factor (λ) was 1.30 for ischemic stroke, 1.52 for ICH, and 1.72 for SAH. Multivariable logistic regression analysis was performed with ischemic stroke as a dependent variable and independent variables including age, sex (0, woman; 1, man), the prevalence of hypertension and diabetes mellitus (0, no history of these conditions; 1, positive history) and genotype of each SNP. Similar analysis was performed with ICH or SAH as a dependent variable and independent variables including age, sex, the prevalence of hypertension and genotype of each SNP. Genotypes of each SNP were assessed according to dominant \[0, AA; 1, AB + BB (A, major allele; B, minor allele)\], recessive (0, AA + AB; 1, BB) and additive genetic models, and the P-value, odds ratio and 95% confidence interval were calculated. Additive models comprised additive 1 (0, AA; 1, AB; 0, BB) and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which were analyzed simultaneously with a single statistical model. The relation of genotypes of SNPs to intermediate phenotypes was examined with Fisher\'s exact test (2×2) or Pearson\'s Chi-square test (2×3). Bonferroni\'s correction was also applied to other statistical analysis as indicated. Statistical tests were performed with JMP Genomics version 6.0 software (SAS Institute, Cary, NC, USA).

Results
=======

EWAS for ischemic stroke
------------------------

The characteristics of the subjects enrolled in the study are shown in [Table I](#tI-ijmm-39-06-1477){ref-type="table"}. Age, the frequency of the male gender, body mass index, and the prevalence of hypertension, diabetes mellitus and chronic kidney disease, as well as systolic and diastolic blood pressure, fasting plasma glucose levels, blood glycosylated hemoglobin (hemoglobin A~1c~) content and serum concentrations of triglycerides and creatinine were greater, whereas the serum concentrations of HDL-cholesterol and estimated glomerular filtration rate were lower, in the subjects with ischemic stroke than in the controls.

We examined the relation of allele frequencies for 41,339 SNPs that passed quality control to ischemic stroke with Fisher\'s exact test. A Manhattan plot of EWAS for ischemic stroke is shown in [Fig. 2](#f2-ijmm-39-06-1477){ref-type="fig"}. After Bonferroni\'s correction, 77 SNPs were found to be significantly (P\<1.21×10^−6^) associated with ischemic stroke ([Table II](#tII-ijmm-39-06-1477){ref-type="table"}). The genotype distributions of these SNPs were in Hardy-Weinberg equilibrium (P\>0.001) among both subjects with ischemic stroke and the controls (data not shown).

Multivariable logistic regression analysis of the relation of SNPs to ischemic stroke
-------------------------------------------------------------------------------------

The relation of the 77 SNPs identified by EWAS to ischemic stroke was examined further by multivariable logistic regression analysis with adjustment for age, sex and the prevalence of hypertension and diabetes mellitus ([Table III](#tIII-ijmm-39-06-1477){ref-type="table"}). Four SNPs, rs3212335 (G/A) of γ-aminobutyric acid type A receptor β3 subunit (*GABRB3*), rs147783135 \[C/T (R692^\*^)\] of transmembrane protease, serine 7 gene (*TMPRSS7*), rs2292661 \[C/T (T391M)\] of protein disulfide isomerase family A member 5 gene (*PDIA5*), and rs191885206 \[T/C (C402R)\] of cytochrome P450 family 4 subfamily F member 12 gene (*CYP4F12*) were related (P\<0.01 in at least one genetic model) to ischemic stroke, although no SNP was significantly \[P\<1.62×10^−4^ (0.05/308)\] associated with this condition. The minor A and C alleles of rs3212335 and rs191885206, respectively, were risk factors for ischemic stroke, whereas the minor T alleles of rs147783135 and rs2292661 were protective against this condition.

EWAS for ICH
------------

The characteristics of the subjects for EWAS for ICH are shown in [Table IV](#tIV-ijmm-39-06-1477){ref-type="table"}. Age, the frequency of the male gender, and the prevalence of hypertension and diabetes mellitus were greater in the subjects with ICH than in the controls.

We examined the relation of allele frequencies for 41,332 SNPs to ICH with Fisher\'s exact test. A Manhattan plot for EWAS for ICH is shown in [Fig. 3A](#f3-ijmm-39-06-1477){ref-type="fig"}. After Bonferroni\'s correction, 48 SNPs were significantly (P\<1.21×10^−6^) associated with ICH ([Table V](#tV-ijmm-39-06-1477){ref-type="table"}). The genotype distributions of these SNPs were in Hardy-Weinberg equilibrium (P\>0.001) both among subjects with ICH and among controls (data not shown).

Multivariable logistic regression analysis of the relation of SNPs to ICH
-------------------------------------------------------------------------

The relation of the 48 SNPs identified by EWAS to ICH was examined further by multivariable logistic regression analysis with adjustment for age, sex and the prevalence of hypertension. A total of 6 SNPs were related (P\<0.05 in at least one genetic model) to ICH ([Table VI](#tVI-ijmm-39-06-1477){ref-type="table"}). Among these SNPs, rs138533962 \[G/A (R379C)\] of serine/threonine/tyrosine kinase 1 gene (*STYK1*) (dominant and additive 1 models) was significantly \[P\<2.60×10^−4^ (0.05/192)\] associated with ICH, with the minor A allele representing a risk factor for this condition.

EWAS for SAH
------------

The characteristics of the subjects in the EWAS for SAH are shown in [Table IV](#tIV-ijmm-39-06-1477){ref-type="table"}. The prevalence of hypertension was greater, whereas that of dyslipidemia was lower, in the subjects with SAH than in the controls.

We examined the relation of allele frequencies for 41,332 SNPs to SAH with Fisher\'s exact test. A Manhattan plot for EWAS for SAH is shown in [Fig. 3B](#f3-ijmm-39-06-1477){ref-type="fig"}. After Bonferroni\'s correction, 12 SNPs were significantly (P\<1.21×10^−6^) associated with SAH ([Table VII](#tVII-ijmm-39-06-1477){ref-type="table"}). The genotype distributions of these SNPs were in Hardy-Weinberg equilibrium (P\>0.001) both among subjects with SAH and among controls (data not shown).

Multivariable logistic regression analysis of the relation of SNPs to SAH
-------------------------------------------------------------------------

The relation of the 12 SNPs identified by EWAS to SAH was examined further by multivariable logistic regression analysis with adjustment for age, sex and the prevalence of hypertension. Three SNPs were related (P\<0.05) to SAH ([Table VIII](#tVIII-ijmm-39-06-1477){ref-type="table"}). Among these SNPs, rs117564807 \[C/T (D919N)\] of collagen type XVII α1 chain gene (*COL17A1*) (dominant and additive 1 models) was significantly \[P\<0.0010 (0.05/48)\] associated with SAH, with the minor T allele being protective against this condition.

Relation of SNPs to intermediate phenotypes
-------------------------------------------

We examined the relation of 6 SNPs (rs3212335 of *GABRB3*, rs147783135 of *TMPRSS7*, rs2292661 of *PDIA5*, rs191885206 of *CYP4F12*, rs138533962 of *STYK1* and rs117564807 of *COL17A1*) to intermediate phenotypes of ischemic or hemorrhagic stroke, including hypertension, diabetes mellitus, hypertriglyceridemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, chronic kidney disease, obesity, and hyperuricemia. The rs138533962 SNP of *STYK1* was significantly \[P\<0.0010 (0.05/48)\] associated with the prevalence of hypertension, diabetes mellitus, hypertriglyceridemia and hypo-HDL-cholesterolemia, whereas the other 5 SNPs were not related to any of these intermediate phenotypes ([Table IX](#tIX-ijmm-39-06-1477){ref-type="table"}).

Relation of genes and SNPs identified in the present study to phenotypes previously examined in GWASs
-----------------------------------------------------------------------------------------------------

We examined the 6 genes and SNPs identified in the present study to phenotypes previously examined by GWASs available in public databases \[GWAS Catalog (<http://www.ebi.ac.uk/gwas>) and GWAS Central (<http://www.gwascentral.org/browser>)\]. None of these genes or SNPs was found to be associated with ischemic or hemorrhagic stroke in previous GWASs (data not shown).

Discussion
==========

The pathogenesis of ischemic stroke is predominantly attributed to atherothrombosis of the cerebral arteries, with its treatable risk factors including hypertension, diabetes mellitus and chronic kidney disease ([@b1-ijmm-39-06-1477]). In addition to these conventional risk factors, genetic variants are important in the development of ischemic stroke ([@b2-ijmm-39-06-1477]). ICH is typically a manifestation of underlying small-vessel disease. Long-standing hypertension can thus lead to hypertensive vasculopathy and consequent microscopic degenerative changes in the walls of small to medium penetrating vessels ([@b13-ijmm-39-06-1477]). Cerebral amyloid angiopathy is characterized by the deposition of the β-amyloid peptide in the walls of small leptomeningeal and cortical vessels, which can also ultimately result in degenerative changes in the vessel wall including loss of smooth muscle cells, wall thickening, luminal narrowing, microaneurysm formation and microhemorrhages ([@b14-ijmm-39-06-1477]--[@b17-ijmm-39-06-1477]). Spontaneous SAH usually results from a ruptured intracranial aneurysm. Blood in the subarachnoid space gives rise to chemical meningitis that commonly increases intracranial pressure for days or a few weeks. Secondary vasospasm may then cause focal brain ischemia. Brain edema accelerates vasospasm and subsequent infarction ([@b21-ijmm-39-06-1477],[@b22-ijmm-39-06-1477]). Given the serious nature of both ischemic and hemorrhagic stroke, prediction of the risk for these conditions on the basis of genetic variants would be of benefit for decision-making with regard to how aggressively to target the clinical risk factors that are currently amenable to treatment.

In this study, we demonstrated that rs3212335 (G/A) of *GABRB3*, rs147783135 \[C/T (R692^\*^)\] of *TMPRSS7*, rs2292661 \[C/T (T391M)\] of *PDIA5* and rs191885206 \[T/C (C402R)\] of *CYP4F12* were related to ischemic stroke in Japanese individuals. The minor A allele of rs3212335 and the C allele of rs191885206 were risk factors for ischemic stroke, whereas the minor T alleles of rs147783135 and rs2292661 were protective against this condition. We also found that rs138533962 \[G/A (R379C)\] of *STYK1* was significantly associated with ICH, with the minor A allele representing a risk factor for ICH, and that rs117564807 \[C/T (D919N)\] of *COL17A1* was significantly associated with SAH, with the minor T allele being protective against this condition.

SNPs associated with ischemic stroke
------------------------------------

The *GABRB3* gene is located at chromosomal region 15q12 (NCBI Gene, <https://www.ncbi.nlm.nih.gov/gene>) and is highly expressed in the brain (The Human Protein Atlas, <http://www.proteinatlas.org>). The GABRB3 protein is a component of a multisub-unit Cl^−^ channel that serves as a receptor for γ-aminobutyric acid (GABA), a major inhibitory neurotransmitter of the mammalian nervous system ([@b41-ijmm-39-06-1477]). Mutations of *GABRB3* have been associated with several disorders, including Angelman syndrome ([@b42-ijmm-39-06-1477]), Prader-Willi syndrome ([@b43-ijmm-39-06-1477]), non-syndromic orofacial clefts ([@b44-ijmm-39-06-1477]), epilepsy ([@b45-ijmm-39-06-1477]) and autism ([@b46-ijmm-39-06-1477]). In this study, we demonstrated that rs3212335 (G/A) of *GABRB3* was related to ischemic stroke, with the minor A allele being a risk factor for this condition, although the molecular mechanism underlying this association remains unclear.

*TMPRSS7* is located at chromosomal region 3q13.2 (NCBI Gene) and is highly expressed in the testis (The Human Protein Atlas). The TMPRSS7 protein belongs to the type II transmembrane serine protease (TTSP) family, the 17 human members of which degrade components of the extracellular matrix ([@b47-ijmm-39-06-1477]) and play physiological and pathological roles in digestion, cardiac function, blood pressure regulation, hearing, iron metabolism, and epithelial homeostasis ([@b48-ijmm-39-06-1477],[@b49-ijmm-39-06-1477]). They have also been implicated in tumor growth, invasion and metastasis ([@b48-ijmm-39-06-1477],[@b49-ijmm-39-06-1477]), and the genetic variants of *TMPRSS7* have been associated with the risk for and prognosis of breast cancer ([@b50-ijmm-39-06-1477]). In this study, we demonstrated that rs147783135 \[C/T (R692^\*^)\] of *TMPRSS7* was related to ischemic stroke, with the minor T allele being protective against this condition. Given the potential roles of *TMPRSS7* in tumor growth and blood pressure regulation ([@b48-ijmm-39-06-1477],[@b49-ijmm-39-06-1477]) the association of this gene with ischemic stroke may reflect an effect on atherosclerosis or blood pressure.

*PDIA5* is located at chromosomal region 3q21.1 (NCBI Gene) and is expressed widely including in the brain and vascular smooth muscle (The Human Protein Atlas). *PDIA5* encodes one of the protein disulfide isomerases that catalyze protein folding and thiol-disulfide interchange reactions in the endoplasmic reticulum (ER). The PDIA5 protein contains an NH~2~-terminal ER signal sequence, three catalytically active thioredoxin domains, a thioredoxin-like domain, and a COOH-terminal ER retention sequence. The thioredoxin-like domain is the primary binding site for the major ER chaperone calreticulin ([@b51-ijmm-39-06-1477],[@b52-ijmm-39-06-1477]). Recent GWASs indicated that a SNP in *PDIA5* was associated with plasma fibrinogen concentration ([@b53-ijmm-39-06-1477]) and platelet count ([@b54-ijmm-39-06-1477]). In this study, we demonstrated that rs2292661 \[C/T (T391M)\] of *PDIA5* was related to ischemic stroke, with the minor T allele being protective against this condition. Given its potential role as a determinant of fibrinogen concentration and platelet count, both of which are important in the development of atherosclerotic thrombosis, the association of *PDIA5* with ischemic stroke may reflect an effect of this gene on arterial thrombosis.

*CYP4F12* is located at chromosomal region 19p13.12 (NCBI Gene) and is expressed in various tissues and organs including the brain and vascular smooth muscle (The Human Protein Atlas). *CYP4F12* encodes a member of the cytochrome P450 superfamily of monooxygenases that catalyze many reactions including those related to drug metabolism, as well as to the synthesis of cholesterol, steroids and other lipids. The CYP4F12 protein is likely localized to the ER ([@b55-ijmm-39-06-1477],[@b56-ijmm-39-06-1477]). Given that human CYP4F enzymes play a role in the metabolism of endogenous compounds such as inflammatory mediators, they likely contribute to regulation of inflammatory processes ([@b57-ijmm-39-06-1477]). Arachidonic acid and prostaglandin H~2~ (PGH~2~) have been found to serve as substrates of CYP4F12, which also metabolizes to a lesser extent PGE~2~, PGF~2α~ and leukotriene B4 ([@b57-ijmm-39-06-1477],[@b58-ijmm-39-06-1477]). In this study, we demonstrated that rs191885206 \[T/C (C402R)\] of *CYP4F12* was related to ischemic stroke, with the minor C allele representing a risk factor for this condition. The association of *CYP4F12* with ischemic stroke may reflect an effect of this gene on vascular inflammation.

*A SNP associated with ICH.* The *STYK1* gene is located at chromosomal region 12p13.2 (NCBI Gene) and is expressed in various tissues and organs, including the brain (The Human Protein Atlas). *STYK1* plays important roles in diverse cellular and developmental processes, including cell proliferation, differentiation and survival ([@b59-ijmm-39-06-1477],[@b60-ijmm-39-06-1477]). The upregulation of *STYK1* expression has been detected in many types of tumor, including breast cancer ([@b61-ijmm-39-06-1477]), lung cancer ([@b62-ijmm-39-06-1477]), ovarian cancer ([@b63-ijmm-39-06-1477]), prostate cancer ([@b64-ijmm-39-06-1477]), colorectal cancer ([@b65-ijmm-39-06-1477]) and hepatocellular carcinoma ([@b66-ijmm-39-06-1477]). The STYK1 protein has been shown to promote cell transformation, tumorigenesis and metastasis by activating the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway and inactivating glycogen synthase kinase 3β signaling ([@b67-ijmm-39-06-1477]). It has also been found to enhance angiogenesis and to change the morphology of blood vessels during tumor growth ([@b68-ijmm-39-06-1477]). In this study, we demonstrated that rs138533962 \[G/A (R379C)\] of *STYK1* was significantly associated with ICH, with the minor A allele representing a risk factor for this condition. The relation of *STYK1* to ICH may be attributable to an effect of this gene on the remodeling of blood vessels in the brain, although the molecular mechanism underlying this association remains to be determined.

*A SNP associated with SAH.* The *COL17A1* gene is located at chromosomal region 10q25.1 (NCBI Gene) and is highly expressed in skin (The Human Protein Atlas). Collagen XVII is a homotrimer of three 180-kDa α1 chains, each of which possesses a long intracellular NH~2~-terminal domain, a short transmembrane region, and an extracellular COOH-terminus. It is a structural component of hemidesmosomes, which mediate the adhesion of epidermal keratinocytes and certain other types of epithelial cell to the underlying basement membrane ([@b69-ijmm-39-06-1477],[@b70-ijmm-39-06-1477]). Mutations in *COL17A1* that result in the generation of premature stop codons are associated with non-Herlitz junctional epidermolysis bullosa ([@b69-ijmm-39-06-1477],[@b70-ijmm-39-06-1477]), which is characterized by generalized blistering of the skin and mucous membranes together with atrophic scarring and nail dystrophy. The majority of patients with such mutations lack type XVII collagen mRNA as a result of nonsense-mediated mRNA decay ([@b71-ijmm-39-06-1477]). In addition, an autoimmune response to collagen XVII is responsible for epidermal impairment in individuals with bullous pemphigoid ([@b72-ijmm-39-06-1477]). A population-based study revealed an association of bullous pemphigoid with neurological disorders, in particular stroke, for which the odds ratio was 3.3 ([@b73-ijmm-39-06-1477]). This association is likely due to the fact that the inflammatory state present in individuals with bullous pemphigoid is not confined to the skin but also involves the vascular endothelium ([@b74-ijmm-39-06-1477],[@b75-ijmm-39-06-1477]). It has been suggested that intracranial aneurysm is a chronic inflammatory disease at bifurcation sites of cerebral arterial walls ([@b76-ijmm-39-06-1477]). Indeed, many inflammatory cells have been detected in specimens of surgically dissected intracranial vessel walls affected by aneurysm ([@b77-ijmm-39-06-1477]). Chronic vascular inflammation, acting together with the structural properties of the cerebral arterial wall and hemodynamic factors, may therefore accelerate the development of intracranial aneurysm and subsequent aneurysm rupture. We have now shown that rs117564807 \[C/T (D919N)\] of *COL17A1* was significantly associated with SAH, with the minor T allele being protective against this condition. The genotype distribution of rs117564807 was 265/265 (100%) CC in subjects with SAH and 8958/9158 (97.82%) CC, 197/9158 (2.15%) CT, and 3/9158 (0.03%) TT in control individuals, giving an allele odds ratio of 0. The association of *COL17A1* with SAH may be attributable to the effect of this gene on cerebrovascular inflammation, although the molecular mechanism remains to be determined.

General considerations
----------------------

In previous meta-analyses of GWASs for ischemic stroke, the MAF of most SNPs ranged from 6 to 49% and the odds ratio from 0.8 to 2.0 ([@b4-ijmm-39-06-1477]--[@b12-ijmm-39-06-1477],[@b34-ijmm-39-06-1477]--[@b36-ijmm-39-06-1477]). In our study, we identified four SNPs related to ischemic stroke, with the allele odds ratio (MAF, %) of rs3212335 of *GABRB3*, rs147783135 of *TMPRSS7*, rs2292661 of *PDIA5*, and rs191885206 of *CYP4F12* being 1.02 (38.9%), 0.54 (0.8%), 0.47 (0.7%), and 2.11 (0.3%), respectively. Whereas rs3212335 of *GABRB3* was thus a common variant with a small effect size, the other three SNPs were low-frequency or rare variants with a moderate effect size.

A meta-analysis of GWASs identified rs11179580 at 12q21.1 and rs156197380 at 1q22 as susceptibility loci for lobar and nonlobar ICH, respectively, in European ancestry populations ([@b20-ijmm-39-06-1477]). The odds ratio (MAF, %) was 1.56 (24%) for rs11179580 and 1.44 (32%) for rs156197380. Previous GWASs ([@b26-ijmm-39-06-1477]--[@b31-ijmm-39-06-1477]) and a meta-analysis of GWASs ([@b32-ijmm-39-06-1477]) also identified SNPs associated with intracranial aneurysm. The MAFs of these SNPs ranged from 15 to 48% and the odds ratios from 0.47 to 2.22. Another recent GWAS of intracranial aneurysm identified low-frequency genetic variants with MAFs of 3 to 5% and odds ratios of \~2.0 ([@b78-ijmm-39-06-1477]). We have now identified two SNPs significantly associated with hemorrhagic stroke, with the odds ratio (MAF, %) of rs138533962 of *STYK1* and rs117564807 of *COL17A1* being 111.3 (2.0%) and 2.23×10^−8^ (1.1%), respectively. Both of these SNPs were thus low-frequency variants with a large effect size.

There are several limitations to the present study: i) The inflation factors for ischemic stroke, ICH, and SAH were relatively high, which may be attributable to the relatively small numbers of subjects with ischemic and hemorrhagic stroke. Given that our results were not replicated, they will require validation in other independent subject panels or in other ethnic groups; ii) it is possible that rs3212335 of *GABRB3*, rs147783135 of *TMPRSS7*, rs2292661 of *PDIA5*, rs191885206 of *CYP4F12*, rs138533962 of *STYK1* or rs117564807 of *COL17A1* is in linkage disequilibrium with other polymorphisms in the same gene or in other nearby genes that are actually responsible for the development of ischemic or hemorrhagic stroke; iii) the functional relevance of these SNPs to the pathogenesis of ischemic stroke, ICH, or SAH remains to be elucidated.

In conclusion, our results suggest that rs3212335 (G/A) of *GABRB3*, rs147783135 \[C/T (R692^\*^)\] of *TMPRSS7*, rs2292661 \[C/T (T391M)\] of *PDIA5*, and rs191885206 \[T/C (C402R)\] of *CYP4F12* may be novel susceptibility loci for ischemic stroke, whereas rs138533962 \[G/A (R379C)\] of *STYK1* and rs117564807 \[C/T (D919N)\] of *COL17A1* may be such loci for ICH and SAH, respectively, in Japanese individuals. Determination of genotypes for these SNPs may prove informative for assessment of the genetic risk for ischemic or hemorrhagic stroke in Japanese individuals.
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###### 

Characteristics of the 10,785 subjects in the exome-wide association study for ischemic stroke.

  Characteristic                    Ischemic stroke   Controls    P-value
  --------------------------------- ----------------- ----------- ----------
  No. of subjects                   1,575             9,210       
  Age (years)                       71.8±12.2         58.8±13.8   \<0.0001
  Sex (male/female, %)              58.9/41.1         50.4/49.6   \<0.0001
  Body mass index (kg/m^2^)         23.5±3.5          23.1±3.5    \<0.0001
  Current or former smoker (%)      33.9              37.2        0.0450
  Hypertension (%)                  79.2              42.4        \<0.0001
  Systolic blood pressure (mmHg)    147±27            125±20      \<0.0001
  Diastolic blood pressure (mmHg)   82±16             75±12       \<0.0001
  Diabetes mellitus (%)             44.0              14.5        \<0.0001
  Fasting plasma glucose (mmol/l)   7.09±2.88         5.80±1.95   \<0.0001
  Blood hemoglobin A1c (%)          6.34±1.42         5.70±0.93   \<0.0001
  Dyslipidemia (%)                  58.7              57.6        0.5082
  Serum triglycerides (mmol/l)      1.47±0.96         1.38±0.96   \<0.0001
  Serum HDL-cholesterol (mmol/l)    1.28±0.42         1.62±0.44   \<0.0001
  Serum LDL-cholesterol (mmol/l)    3.10±0.98         3.13±0.80   0.0208
  Chronic kidney disease (%)        36.8              18.8        \<0.0001
  Serum creatinine (*µ*mol/l)       90.3±115.5        72.9±6804   \<0.0001
  eGFR (ml m^−1^ 1.73 m^−2^)        67.7±22.7         74.0±18.1   \<0.0001
  Hyperuricemia (%)                 16.9              16.1        0.4794
  Serum uric acid (*µ*mol/l)        329±96            323±90      0.1073

Quantitative data are the means ± SD and were compared between subjects with ischemic stroke and controls with the Mann-Whitney U test. Categorical data were compared between the 2 groups with Fisher\'s exact test. Based on Bonferroni\'s correction, a P-value of \<0.0026 (0.05/19) was considered statistically significant. HDL, high density lipoprotein; LDL, low density lipoprotein.

###### 

The 77 SNPs significantly (P\<1.21×10^−6^) associated with ischemic stroke in the exome-wide association study.

  Gene             dbSNP         Nucleotide (amino acid) substitution[a](#tfn2a-ijmm-39-06-1477){ref-type="table-fn"}   Chromosome: position   MAF (%)   P-value (allele)   Allele OR   95% CI
  ---------------- ------------- -------------------------------------------------------------------------------------- ---------------------- --------- ------------------ ----------- ------------
  *TTLL5*          rs2833270     C/T                                                                                    21: 3115036            4.1       5.45×10^−112^      1.05        0.87--1.27
                   rs605066      C/T                                                                                    6: 139508529           25.6      1.93×10^−89^       1.02        0.94--1.11
                   rs146036604   A/C (L879F)                                                                            14: 75783181           1.4       1.09×10^−73^       0.90        0.65--1.25
                   rs12615742    T/C                                                                                    2: 37768584            47.3      3.80×10^−62^       1.04        0.96--1.12
  *TCEB3B*         rs2010834     A/C (F254C)                                                                            18: 47034504           24.5      2.40×10^−61^       1.02        0.94--1.11
  *TCF19*          rs3130933     G/A                                                                                    6: 31164308            5.2       1.05×10^−53^       1.18        1.00--1.39
  *GABRB3*         rs3212335     G/A                                                                                    15: 26766994           38.9      8.21×10^−53^       1.02        0.94--1.11
  *NRXN3*          rs6574433     G/A                                                                                    14: 78319816           26.5      6.14×10^−49^       0.98        0.90--1.06
  *UBASH3A*        rs11203203    G/A                                                                                    21: 42416077           3.9       7.70×10^−44^       1.13        0.93--1.37
  *TBC1D32*        rs79221470    T/A (C505S)                                                                            6: 121281639           17.8      5.10×10^−37^       1.01        0.92--1.11
  *DBT*            rs140308307   T/C (N13D)                                                                             1: 100249784           0.3       2.69×10^−36^       1.59        0.86--2.94
  *IL20RA*         rs191996643   T/C (I43V)                                                                             6: 137017065           0.8       2.63×10^−31^       0.74        0.47--1.18
  *MMP28*          rs117651561   G/A                                                                                    17: 35766644           13.6      1.80×10^−29^       1.01        0.90--1.12
  *C15orf57*       rs3803354     T/C                                                                                    15: 40564790           8.9       3.88×10^−27^       1.11        0.98--1.27
  *TMPRSS7*        rs147783135   C/T (R692^\*^)                                                                         3: 112081004           0.8       3.41×10^−26^       0.54        0.31--0.94
                   rs7752978     A/G                                                                                    6: 114869897           47.4      1.29×10^−24^       1.00        0.92--1.08
  *HMGCS2*         rs181428774   G/T (L59M)                                                                             1: 119764556           0.3       1.56×10^−24^       0.49        0.21--1.14
  *DPF3*           rs757572      T/C                                                                                    14: 72665321           41.2      1.28×10^−21^       1.07        0.99--1.15
  *SLC6A4*         rs56316081    T/C (I108V)                                                                            17: 30221637           0.1       2.54×10^−21^       ND          ND
  *OSGEPL1*        rs75321854    C/T (A98T)                                                                             2: 189755490           4.8       2.31×10^−20^       1.10        0.93--1.31
  *S100A3*         rs36022742    C/T (R3K)                                                                              1: 153548478           1.6       4.16×10^−20^       0.77        0.55--1.09
  *ALMS1*          rs3820700     G/A (S2576N)                                                                           2: 73489683            26.1      6.70×10^−20^       0.98        0.90--1.08
  *OR2D2*          rs1965209     A/G (S148P)                                                                            11: 6892059            12.2      9.24×10^−20^       1.11        0.99--1.24
                   rs9494145     T/C                                                                                    6: 135111414           31.8      9.77×10^−20^       0.96        0.88--1.04
  *AXDND1*         rs41267592    C/T (T627M)                                                                            1: 179468524           0.3       1.92×10^−19^       0.61        0.28--1.33
  *SCMH1*          rs182666831   A/T (S48C)                                                                             1: 41151649            0.1       5.23×10^−19^       0.58        0.18--1.92
  *ELMO1*          rs11984075    A/G                                                                                    7: 37397251            1.1       3.61×10^−18^       0.78        0.53--1.16
  *OTOL1*          rs12633334    G/A                                                                                    3: 161452823           45.1      2.34×10^−17^       0.97        0.89--1.04
                   rs5026743     T/G                                                                                    6: 32472187            29.7      4.27×10^−17^       1.12        1.03--1.22
  *MUC16*          rs12459532    G/A (P9422L)                                                                           19: 8948505            1.8       4.29×10^−17^       1.42        1.10--1.85
  *TMPRSS6*        rs2235321     G/A                                                                                    22: 37066886           43.7      7.08×10^−17^       1.09        1.01--1.18
                   rs11624336    G/A                                                                                    14: 96727175           14.9      2.40×10^−16^       0.99        0.88--1.10
  *KIAA1324*       rs1052878     C/T (P922L)                                                                            1: 109202996           4.9       6.66×10^−16^       1.05        0.89--1.24
  *MMP28*          rs79742527    G/A                                                                                    17: 35766662           13.6      1.04×10^−15^       1.00        0.89--1.11
  *SERINC1*        rs11964202    G/A                                                                                    6: 122444993           0.6       1.64×10^−15^       0.87        0.51--1.47
  *KANK4*          rs2258470     C/T (R822H)                                                                            1: 62263166            19.3      8.84×10^−15^       1.13        1.03--1.24
  *PRR22*          rs201451364   C/T (R78H)                                                                             19: 5784014            0.1       1.42×10^−14^       1.54        0.57--4.13
  *PLCB1*          rs6140742     C/G                                                                                    20: 8838465            36.3      3.52×10^−14^       1.01        0.94--1.09
  *AHNAK2*         rs150385420   A/G (S4485P)                                                                           14: 104941998          2.6       6.43×10^−14^       0.98        0.77--1.23
  *FBXO16*         rs3735726     C/T (R63Q)                                                                             8: 28463730            3.3       4.02×10^−13^       1.14        0.93--1.39
  *CALR3*          rs3810198     T/C                                                                                    19: 16490383           28.6      1.45×10^−12^       1.03        0.95--1.12
  *PDGFD*          rs10895547    C/T                                                                                    11: 103937424          41.0      1.74×10^−12^       0.99        0.92--1.07
  *LOC101928877*   rs6844558     T/C                                                                                    4: 185060282           38.5      4.86×10^−11^       1.02        0.94--1.10
  *MBD2*           rs1145315     T/C                                                                                    18: 54162585           33.3      1.47×10^−10^       0.95        0.88--1.03
  *LRTM1*          rs182902370   C/T                                                                                    3: 54918891            0.9       3.41×10^−10^       1.10        0.74--1.62
  *SEC16B*         rs202187751   G/C (D41H)                                                                             1: 177967861           0.2       4.18×10^−10^       0.53        0.16--1.72
  *NEURL4*         rs117553236   T/G (M1048L)                                                                           17: 7321417            0.3       5.35×10^−10^       0.97        0.41--2.33
  *PPFIA1*         rs546502      G/A (V71I)                                                                             11: 70272383           15.9      6.09×10^−10^       1.18        1.08--1.30
  *SLC18A1*        rs1390938     G/A (T136I)                                                                            8: 20179202            25.5      6.98×10^−10^       1.06        0.97--1.15
  *DDOST*          rs74526704    C/T (R396Q)                                                                            1: 20652655            0.2       9.25×10^−10^       0.86        0.34--2.20
  *ZNF16*          rs139521477   C/T (R669Q)                                                                            8: 144930781           0.1       9.85×10^−10^       0.73        0.22--2.43
  *TTC16*          rs142193455   G/A (R450Q)                                                                            9: 127726328           1.1       1.05×10^−9^        0.60        0.38--0.93
  *SEMA4D*         rs13295305    C/T (R713K)                                                                            9: 89363482            12.7      1.24×10^−9^        1.07        0.96--1.20
  *TRH*            rs13306057    G/A (G3S)                                                                              3: 129975823           0.2       1.47×10^−9^        0.44        0.14--1.41
  *MAST4*          rs56337909    G/A (S1863N)                                                                           5: 67164767            2.7       3.19×10^−9^        1.01        0.79--1.28
  *PTPRR*          rs10784867    C/T                                                                                    12: 70740947           48.3      4.83×10^−9^        0.98        0.91--1.06
  *PREX1*          rs6095241     G/A                                                                                    20: 48692260           41.5      4.95×10^−9^        1.09        1.01--1.18
                   rs12402711    G/A                                                                                    1: 41413409            27.1      6.95×10^−9^        1.00        0.92--1.09
                   rs10277516    C/A                                                                                    7: 22869155            3.3       2.30×10^−8^        1.08        0.88--1.33
  *ROR2*           rs200805854   C/A (E703D)                                                                            9: 91724385            0.2       3.93×10^−8^        0.89        0.35--2.27
  *DUS4L*          rs4730250     A/G                                                                                    7: 107567250           9.4       4.04×10^−8^        0.91        0.80--1.04
                   rs11185362    A/G                                                                                    1: 104018866           24.2      4.37×10^−8^        1.04        0.96--1.14
  *IL7R*           rs3194051     A/G (I356V)                                                                            5: 35876172            7.4       6.06×10^−8^        1.01        0.87--1.16
  *FAM200A*        rs75129401    T/C (H35R)                                                                             7: 99548304            1.5       6.08×10^−8^        0.64        0.44--0.93
  *PLXNC1*         rs75674989    G/T (R614S)                                                                            12: 94226656           3.8       6.12×10^−8^        0.84        0.68--1.03
                   rs7131744     G/A                                                                                    12: 4387114            44.7      7.92×10^−8^        1.09        1.01--1.18
  *PDIA5*          rs2292661     C/T (T391M)                                                                            3: 123150263           0.7       1.03×10^−7^        0.47        0.26--0.88
  *GOLGB1*         rs3732407     G/C (S911T)                                                                            3: 121697776           3.5       1.11×10^−7^        1.15        0.94--1.41
  *ARPC1B*         rs1045012     G/C (K37N)                                                                             7: 99386731            1.7       1.97×10^−7^        0.94        0.70--1.27
  *ALMS1*          rs138921247   G/C (V807L)                                                                            2: 73448943            1.8       2.71×10^−7^        0.87        0.65--1.16
  *TRIM67*         rs1998027     A/G                                                                                    1: 231190340           33.7      2.80×10^−7^        0.98        0.90--1.06
  *C16orf95*       rs3748393     A/C (S26A)                                                                             16: 87317167           41.7      3.24×10^−7^        1.06        0.98--1.14
  *CES5A*          rs145397395   C/T (V220M)                                                                            16: 55866010           0.9       4.76×10^−7^        0.85        0.76--1.79
  *ACTR5*          rs3752289     C/T (P580L)                                                                            20: 38771731           1.4       5.15×10^−7^        0.98        0.71--1.36
                   rs3095354     A/G                                                                                    6: 30868334            26.7      5.75×10^−7^        1.12        1.03--1.22
  *CYP4F12*        rs191885206   T/C (C402R)                                                                            19: 15696024           0.3       6.57×10^−7^        2.11        1.23--3.57
  *CELSR2*         rs117684956   G/A (V598M)                                                                            1: 109251871           1.3       9.21×10^−7^        1.25        0.93--1.69

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. SNP, single nucleotide polymorphisms; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; ND, not determined.

###### 

Relation of SNPs to ischemic stroke as determined by multivariable logistic regression analysis.

  SNP           Dominant         Recessive   Additive 1          Additive 2                                                             
  ------------- ---------------- ----------- ------------------- ------------ ------------------- -------- ------------------- -------- -------------------
  rs3212335     G/A              0.6428                          0.0036       1.29 (1.09--1.53)   0.5896                       0.0150   1.26 (1.05--1.52)
  rs147783135   C/T (R692^\*^)   0.0024      0.37 (0.16--0.72)   0.4322                           0.0029   0.38 (0.17--0.74)   0.4296   
  rs2292661     C/T (T391M)      0.0054      0.35 (0.14--0.76)   ND                               0.0054   0.35 (0.14--0.76)   ND       
  rs191885206   T/C (C402R)      0.0082      2.60 (1.30--4.93)   ND                               0.0082   2.60 (1.30--4.93)   ND       

Multivariable logistic regression analysis was performed with adjustment for age, sex and the prevalence of hypertension and diabetes mellitus. Based on Bonferroni\'s correction, a P-value of \<1.62×10^−4^ (0.05/308) was considered statistically significant. SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; ND, not determined.

###### 

Characteristics of the subjects in the exome-wide association studies for ICH or subarachnoid hemorrhage.

  Characteristic                 Controls    ICH         P-value    SAH         P-value
  ------------------------------ ----------- ----------- ---------- ----------- ----------
  No. of subjects                9158        673                    265         
  Age (years)                    58.8±13.9   69.4±13.9   \<0.0001   59.4±13.2   0.8515
  Sex (male/female, %)           50.4/49.6   62.6/37.4   \<0.0001   41.1/58.9   0.0033
  Body mass index (kg/m^2^)      23.1±3.5    23.1±3.8    0.9986     23.1±3.3    0.9672
  Current or former smoker (%)   37.1        33.3        0.1836     31.5        0.1590
  Hypertension (%)               42.4        81.4        \<0.0001   60.5        \<0.0001
  Diabetes mellitus (%)          14.5        38.1        \<0.0001   19.6        0.0345
  Dyslipidemia (%)               57.5        51.5        0.0152     41.2        \<0.0001
  Chronic kidney disease (%)     18.8        21.2        0.2656     28.0        0.0052
  Hyperuricemia (%)              16.0        15.6        0.8915     9.4         0.0060

Quantitative data are the means ± SD and were compared between subjects with ICH or SAH and controls with the Mann-Whitney U test. Categorical data were compared between 2 groups with Fisher\'s exact test. Based on Bonferroni\'s correction, a P-value of \<0.0028 (0.05/18) was considered statistically significant. ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

###### 

The 48 SNPs significantly (P\<1.21×10^−6^) associated with intracerebral hemorrhage in the exome-wide association study.

  Gene             dbSNP         Nucleotide (amino acid) substitution[a](#tfn5a-ijmm-39-06-1477){ref-type="table-fn"}   Chromosome: position   MAF (%)   P-value (allele)   Allele OR   95% CI
  ---------------- ------------- -------------------------------------------------------------------------------------- ---------------------- --------- ------------------ ----------- --------------
  *RECQL*          rs146924988   A/G (M1T)                                                                              12: 21499569           0.3       8.57×10^−103^      0.93        0.29--3.00
  *ATF7IP2*        rs13335336    A/G                                                                                    16: 10465406           17.0      3.91×10^−93^       1.15        1.00--1.33
  *SHCBP1*         rs11545690    A/C (M60R)                                                                             16: 46618297           5.3       3.58×10^−76^       0.87        0.67--1.13
                   rs1405262     T/C                                                                                    2: 5994808             41.3      6.36×10^−70^       0.98        0.88--1.10
  *CAT*            rs7943316     A/T                                                                                    11: 34438925           33.7      1.49×10^−53^       1.02        0.91--1.15
  *EXOC6B*         rs1517182     C/A                                                                                    2: 72508184            1.7       8.40×10^−52^       0.91        0.59--1.41
  *RNASE10*        rs202109789   G/A (G87S)                                                                             14: 20510730           0.2       3.52×10^−49^       1.00        0.31--3.25
  *GKN2*           rs146849599   C/T (V130M)                                                                            2: 68946388            2.7       6.04×10^−49^       0.82        0.57--1.18
  *IGSF10*         rs78090556    G/A (T981M)                                                                            3: 151447039           0.2       1.49×10^−48^       2.57        1.08--6.25
  *GFM2*           rs77099085    G/T (H92N)                                                                             5: 74759397            6.4       5.68×10^−46^       0.93        0.74--1.17
  *ADRB2*          rs1042713     G/A (G16R)                                                                             5: 148826877           49.1      4.57×10^−36^       1.02        0.92--1.15
  *SPN*            rs3764276     C/T                                                                                    16: 29661882           37.3      5.46×10^−36^       1.13        1.01--1.26
                   rs3135365     T/G                                                                                    6: 32421478            18.9      4.03×10^−32^       0.99        0.85--1.14
  *NAA25*          rs12231744    C/T (R876K)                                                                            12: 112039251          35.1      1.00×10^−30^       1.14        1.02--1.28
  *DNAH11*         rs78763603    G/A                                                                                    7: 21698150            15.3      3.69×10^−24^       0.99        0.85--1.15
  *C15orf57*       rs3803354     T/C                                                                                    15: 40564790           8.9       6.29×10^−24^       0.92        0.76--1.12
  *BDP1*           rs34529158    C/A (P1669Q)                                                                           5: 71522303            0.5       3.02×10^−23^       0.94        0.44--2.04
  *FLG*            rs2184953     G/A (H2194Y)                                                                           1: 152308306           36.2      9.10×10^−21^       0.98        0.88--1.10
                   rs563694      T/G                                                                                    2: 168917561           2.1       1.75×10^−20^       1.24        0.85--1.79
  *LOC100996813*   rs2453589     G/A                                                                                    17: 19585538           26.0      8.53×10^−19^       1.09        0.96--1.23
  *DPF3*           rs757572      T/C                                                                                    14: 72665321           41.2      2.14×10^−17^       1.03        0.93--1.16
  *CCDC18*         rs3820059     G/A (S172F)                                                                            1: 169421916           7.1       2.24×10^−15^       0.98        0.79--1.22
                   rs11624336    G/A                                                                                    14: 96727175           14.9      1.56×10^−14^       0.99        0.84--1.15
  *AXDND1*         rs41267592    C/T (T627M)                                                                            1: 179468524           0.3       1.65×10^−14^       0.62        0.19--1.97
                   rs13234712    G/A                                                                                    7: 119939419           38.8      1.39×10^−13^       0.98        0.88--1.10
  *MAPT*           rs3785879     C/A                                                                                    17: 45908270           40.8      8.89×10^−12^       0.95        0.85--1.06
  *NLRP13*         rs17711239    T/C (N781S)                                                                            19: 55907897           9.3       1.57×10^−11^       1.05        0.87--1.27
  *AIF1*           rs2857697     A/G                                                                                    6: 31617442            34.1      1.84×10^−11^       1.19        1.06--1.34
  *STYK1*          rs138533962   G/A (R379C)                                                                            12: 10620278           2.0       3.90×10^−11^       401.7       100.0--995.0
  *CCDC169*        rs9546897     T/C (K120R)                                                                            13: 36254100           34.6      3.74×10^−10^       1.04        0.93--1.16
  *HMHA1*          rs150294461   G/A (G654E)                                                                            19: 1080682            1.4       4.63×10^−10^       1.12        0.69--1.79
  *TJP3*           rs1046268     C/T (T898M)                                                                            19: 3750617            29.5      5.56×10^−10^       1.00        0.88--1.13
  *PAX5*           rs2297105     A/C                                                                                    9: 37020625            48.3      7.69×10^−10^       0.98        0.88--1.09
                   rs4996815     G/T                                                                                    13: 105999312          12.6      8.66×10^−10^       1.03        0.88--1.22
  *HLA-DPB1*       rs9277471     A/G                                                                                    6: 33085905            43.6      1.55×10^−9^        1.01        0.90--1.12
  *SSC4D*          rs10227141    C/T (R505G)                                                                            7: 76390273            14.4      4.91×10^−9^        0.94        0.80--1.10
  *ZCCHC11*        rs138145860   A/G (I1270T)                                                                           1: 52445800            0.2       1.04×10^−8^        0.93        0.29--2.99
  *MOGAT1*         rs35959734    G/A (A13T)                                                                             2: 222671822           1.2       1.11×10^−8^        0.82        0.49--1.39
                   rs6534076     C/T                                                                                    4: 118030971           38.4      1.38×10^−8^        0.96        0.85--1.07
  *SPATC1L*        rs113710653   C/T (E231K)                                                                            21: 46161921           1.9       3.75×10^−8^        3.64        2.43--5.44
  *LRRC17*         rs3800939     A/G (K119E)                                                                            7: 102934268           14.0      3.90×10^−8^        0.97        0.82--1.13
  *PATE1*          rs2114084     A/G (Q47R)                                                                             11: 125747715          36.4      2.19×10^−7^        1.10        0.98--1.23
  *LY6G6C*         rs117894946   G/C (G75A)                                                                             6: 31719250            9.5       2.77×10^−7^        1.06        0.88--1.28
  *VWA5B1*         rs139281890   G/A (R92Q)                                                                             1: 20312971            0.2       3.26×10^−7^        0.44        0.06--3.23
  *PABPC4*         rs4660293     A/G                                                                                    1: 39562508            15.2      3.99×10^−7^        1.10        0.95--1.28
  *ELMO1*          rs11984075    A/G                                                                                    7: 37397251            1.1       5.49×10^−7^        1.04        0.62--1.74
  *C2*             rs511294      A/C                                                                                    6: 31921092            0.6       7.29×10^−7^        1.20        0.63--2.30
                   rs2823962     G/A                                                                                    21: 16673913           32.8      8.40×10^−7^        0.99        0.88--1.11

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.

###### 

Relation of SNPs to intracerebral hemorrhage as determined by multivariable logistic regression analysis.

  SNP           Dominant      Recessive           Additive 1            Additive 2                                                                             
  ------------- ------------- ------------------- --------------------- ------------ ---------------------- ------------------- --------------------- -------- ----------------------------
  rs3764276     C/T           0.0377              1.21 (1.01--1.45)     0.3181                              0.0634                                    0.1001   
  rs3820059     G/A (S172F)   0.6828                                    0.0091       2.6×10^−8^ (0--0.55)   0.4378                                    0.0095   2.6×10^−8^ (0--5.5×10^−7^)
  rs2857697     A/G           0.0444              1.20 (1.00--1.43)     0.0176       1.36 (1.06--1.74)      0.1876                                    0.0073   1.46 (1.11--1.90)
  rs138533962   G/A (R379C)   **\<1.0×10^−23^**   111.3 (33.0--694.6)   ND                                  **\<1.0×10^−23^**   111.3 (33.0--694.6)   ND       
  rs113710653   C/T (E231K)   0.0020              2.35 (1.39--3.78)     0.6760                              0.0018              2.38 (1.41--3.83)     0.6804   
  rs3800939     A/G (K119E)   0.8551                                    0.0414       0.44 (0.15--0.97)      0.5338                                    0.0466   0.44 (0.16--0.99)

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension. Based on Bonferroni\'s correction, P-values of \<2.60×10^−4^ (0.05/192) were considered statistically significant and are shown in bold. SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; ND, not determined.

###### 

The 12 SNPs significantly (P\<1.21×10^−6^) associated with subarachnoid hemorrhage in the exome-wide association study.

  Gene        dbSNP         Nucleotide (amino acid) substitution[a](#tfn7a-ijmm-39-06-1477){ref-type="table-fn"}   Chromosome: position   MAF (%)   P-value (allele)   Allele OR   95% CI
  ----------- ------------- -------------------------------------------------------------------------------------- ---------------------- --------- ------------------ ----------- ------------
  *CDL6*      rs2972146     A/C                                                                                    2: 226235982           8.7       1.28×10^−18^       0.98        0.72--1.33
              rs3135365     T/G                                                                                    6: 32421478            18.9      9.71×10^−15^       0.86        0.68--1.09
              rs2282978     T/C                                                                                    7: 92635096            10.6      3.91×1^0−12^       1.23        0.95--1.59
              rs2639889     A/G                                                                                    16: 61089243           32.3      4.23×10^−11^       0.88        0.72--1.06
  *ANKFN1*    rs12449568    T/C                                                                                    17: 56352794           42.0      3.64×10^−10^       0.92        0.77--1.09
  *CHRDL2*    rs79893604    G/A (P395L)                                                                            11: 74697229           0.8       5.70×10^−10^       2.45        1.23--4.76
  *CTNNA3*    rs12256826    C/T                                                                                    10: 66214832           13.6      8.96×10^−10^       0.83        0.63--1.09
  *SLC4A5*    rs10177833    A/C                                                                                    2: 74230591            46.8      7.03×10^−9^        0.99        0.84--1.18
  *TEX41*     rs2381683     A/G                                                                                    2: 144981989           2.7       1.15×10^−8^        1.14        0.67--1.91
  *PYGM*      rs589691      T/C                                                                                    11: 64757744           42.2      1.25×10^−8^        1.06        0.89--1.27
              rs34429154    A/C                                                                                    1: 4303675             40.2      1.47×10^−8^        1.04        0.87--1.24
  *COL17A1*   rs117564807   C/T (D919N)                                                                            10: 104040357          1.1       4.83×10^−7^        0.00        ND

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; ND, not determined.

###### 

Relation of SNPs to subarachnoid hemorrhage as determined by multivariable logistic regression analysis.

  SNP           Dominant      Recessive    Additive 1                   Additive 2                                                                                   
  ------------- ------------- ------------ ---------------------------- ------------ ---------------------------- ------------ ---------------------------- -------- ----------------------------
  rs2639889     A/G           0.0203       0.74 (0.58--0.96)            0.9267                                    0.0129       0.71 (0.55--0.93)            0.5252   
  rs12256826    C/T           0.5019                                    0.0024       2.2×10^−8^ (0--6.1×10^−4^)   0.8687                                    0.0024   2.2×10^−8^ (0--1.1×10^−4^)
  rs117564807   C/T (D919N)   **0.0009**   2.2×10^−8^ (0--3.7×10^−4^)   0.6615                                    **0.0009**   2.2×10^−8^ (0--1.1×10^−4^)   0.6583   

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension. Based on Bonferroni\'s correction, P-values of \<0.0010 (0.05/48) were considered statistically significant and are shown in bold. SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval.

###### 

Relation of SNPs to intermediate phenotypes of ischemic or hemorrhagic stroke.

  SNP                                           Hypertension       DM                Hyper-TG     Hypo-HDL           Hyper-LDL   CKD      Obesity   HU
  ---------------------------- ---------------- ------------------ ----------------- ------------ ------------------ ----------- -------- --------- --------
  Related to ischemic stroke                                                                                                                        
  rs3212335                    G/A              0.1945             0.7378            0.3226       0.3391             0.2901      0.8774   0.1276    0.0084
  rs147783135                  C/T (R692^\*^)   0.5725             0.0957            0.6348       0.9054             0.4731      0.6812   0.5797    0.8922
  rs2292661                    C/T (T391M)      0.2069             0.2699            0.9279       0.8970             0.4782      0.2028   0.7069    0.3671
  rs191885206                  T/C (C402R)      1.0000             0.8703            0.1862       0.4469             0.5154      0.8764   1.0000    0.1129
  Related to ICH                                                                                                                                    
  rs138533962                  G/A (R379C)      **4.55×10^−13^**   **7.12×10^−5^**   **0.0002**   **1.81×10^−13^**   0.0765      1.0000   0.5188    1.0000
  Related to SAH                                                                                                                                    
  rs117564807                  C/T (D919N)      0.7052             0.5715            0.2072       0.2934             0.1943      0.1056   0.5019    0.1484

Data are shown as P-values. The prevalence of each condition was compared among genotypes with Fisher\'s exact test (2×2) or Pearson\'s Chi-square test (2×3). Based on Bonferroni\'s correction, P-values of \<0.0010 (0.05/48) were considered statistically significant and are shown in bold. SNPs, single nucleotide polymorphisms; DM, diabetes mellitus; hyper-TG, hypertriglyceridemia; hypo-HDL, hypo-HDL-cholesterolemia; hyper-LDL, hyper-LDL-cholesterolemia; CKD, chronic kidney disease; HU, hyperuricemia; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.
